Metformin

The reviewed healthy-aging outcomes include function, cognition and biological measures. Comparisons in which both groups receive lifestyle therapy need to isolate what adding metformin changes.

A change in a laboratory marker, a test score and everyday function are different outcomes. A statistically detectable result does not by itself tell us whether someone would notice a worthwhile difference.

Check the measured endpoint, comparison and study population. The full profile preserves effect estimates and the source's clinical-significance assessment, including when that assessment is not supplied.

The claim to test: Metformin is an established anti-aging treatment for healthy people.

What the reviewed records say:

The gap: Disease context and combination treatment limit attribution. An unfavorable biomarker classification is not automatically demonstrated clinical harm.

Durability, effects in other populations and healthy-lifespan outcomes need their own evidence.

Independent replication, meaningful human outcomes, longer follow-up and better safety reporting would make these results easier to interpret.

Disease context and combination treatment limit attribution. An unfavorable biomarker classification is not automatically demonstrated clinical harm.